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Poster Session I S213most effective cord blood processing method results in the highest
total nucleated cell (TNC) count recovery with RBC volume of
\20 ml. In order to determine the most efficient automated and
manual processes, we compared units RBC-depleted by elutriation
(Sepax) with units that were RBC-depleted manually. Sepax process-
ing was performed with final processing volumes of 45 ml
(n5 1001), 35 ml (n5 18) or 25 ml (n5 9); manual processing was
performed by removing the equivalent of 0-40% of the starting vol-
ume from the RBC pellet (40% n5 17; 30% n5 9); 20% n5 14;
10% n5 6 and 0% n5 18). The TNC recoveries of units processed
by Sepax were equivalent at 45 ml (88%), 35 ml (87%), and 25 ml
(88%). Units processed with manual RBC depletion resulted in de-
creased TNC recoveries with greater RBC depletion (90% recovery
at 0% reduction vs. 81% TNC recovery at 40% reduction). The
mean final RBC volumes were significantly lower in the units pro-
cessed by Sepax (5.9 ml at 25 ml; 9.5 ml at 35 ml; 14.6 ml at 45 ml)
compared to the units that were manually RBC-depleted (17 ml at
40% reduction vs. 27 ml at 0% reduction). We conclude that RBC
depletion to \20 ml can be routinely achieved with any Sepax
method or by manual depletion of 40% of the starting volume
from the RBC pellet.HEMATOPOIESIS/MESENCHYMAL CELLS
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THE USE OF F-18 THYMIDINE IMAGING FOR EVALUATION OF THE BONE
MARROW COMPARTMENT FOLLOWING TRANSPLANTATION
Holter, J.L.1, Awasthi, V.2, Thorp, K.K.1, Anderson, S.4, Chacko, G.N.3,
Epstein, R.1 1University of Oklahoma, Oklahoma City, OK; 2University
of Oklahoma, Oklahoma City, OK; 3Oklahoma Pet Center, Oklahoma
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Evaluation of engraftment following bonemarrow transplantation
is based on measurements of marrow growth including peripheral
blood counts and bone marrow biopsies done weeks following trans-
plant. Early prediction of marrow function becomes increasingly
necessary as cord blood use increases, in evaluation of intentional
or unintentional radiation exposure, for evaluation of minimal resid-
ual disease, and to maximize treatment efficacy in hematologic ma-
lignancies. F-18 Flourothymidine (FLT)/PET imaging is being
evaluated clinically for tumor detection and staging. Unlike the
more commonly used FDG/PET, FLT is tied to proliferative activ-
ity and cellular growth by thymidine’s inclusion into DNA, and is
therefore less hampered by inflammatory background. We describe
the use of FLT in two groups, 1) a rat model of ablative and non-
myeloablative transplantation, and 2) normal and lymphoma patients
undergoing treatment.
In our rat model, we evaluated if imaging could provide early
evidence of hematopoietic recovery following radiation and trans-
plantation. Rats received myeloablative, non-myeloablative, and
sham transplantation with imaging at baseline, 24-48 hours after
transplantation and 6 days post-transplantation. As seen in Table
1, analysis confirms that FLT predicts engraftment as early as
24-48 hours following transplantation, FLT also can predict
lack of engraftment and radiation effect in sham transplantations
who did not receive stem cell infusion. Figure 1 illustrates FLT
and FDG imaging performed in a normal, post radiation and
post transplant rat, confirming superiority of FLT in evaluating
marrow function.
In our humanmodel, we evaluated if imaging could be used to pro-
vide useful information about chemotherapeutic and radiation ef-
fects on marrow. We imaged 6 patients with intracranial
malignancy with normal bone marrow as controls. In addition, we
imaged 3 lymphoma patients prior to treatment, at day 9 post-che-
motherapy, and following six cycles of chemotherapy. Figure 2 illus-
trates differences seen in FLT in a patient with normal marrow and
a patient with known marrow involvement. Our human and animal
model confirm that FLT can be used as a marker of cellular prolifer-
ation in the bone marrow. We propose that this tool could be used
for early evaluation of engraftment, success of chemotherapy,
prediction of radiation injury, and evaluation of minimal residual
disease.Table 1. ImagingCharacteristics of Experimental Animals and
Histologic Correlations
FLT FDG
Experimental Rat
Subsets
studies
performed
studies
performed Histologic CorrelationNormal/Baseline
rat studiesn5 10 n5 6 Normal cellular
marrow24-48 hrs post
950 cGy TBIn5 6 n5 4 Marrow damage
hypocellularityDay 7 post 950 cGy
TBIn5 4 not performed Aplastic marrowDay 6-7 post
950 cGy TBI
(4-5 days post
transplantation)n5 4 n5 4 Focal areas of
cellular
regenerationDay 10 post
950 cGy TBI
(6 days post
transplantationn5 4 n5 2 Cellular marrowDay 6-7 post
500 cGy TBI (no
transplantation)n5 6 not performed Moderate
hypocellularity149
SUICIDE CASPASE 9 GENE FOR IMPROVED SAFETY OF THERAPIES USING
MESENCHYMAL STROMAL CELLS
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AlthoughMSC have been administered to hundreds of patients so
far withminimal reported side effects, little is known about their long
term effects. Recent reports of osteosarcoma formation in culture
and interference with major organ function due to ectopic ossifica-
tion raise safety concerns. In light of these, we sought to develop
a system allowing control over the growth and survival of MSCs ad-
ministered therapeutically, using an inducible caspase-9 (iCasp9)
protein that can be activated by a specific chemical inducer of dimer-
ization (CID) leading to cell death.
MSCs from healthy donors were retrovirally transduced with
iCasp9 linked to a truncated form of CD19, allowing selection
of transduced cells: 476 6% of the cells were iCasp9+, a percent-
age stable over more than two weeks in culture, suggesting no
deleterious or growth advantageous effects of the construct on
MSCs. iCasp9+ cells were easily immunomagnetically selected.
Phenotype (.99% CD73+CD90+CD105+, and negative for he-
matopoietic markers) and differential potential of iCasp9+ cells
was identical to that of untransduced cells, proving the genetic
manipulation of MSCs did not modify their basic characteristics.
Non-transduced MSCs had a spontaneous rate of apoptosis in
culture 18% (67%), similar to iCasp9+ cells at baseline
(156 6%, P5 0.47). Addition of CID to cultures after transduc-
tion resulted in apoptotic death of .90% of iCasp9+ cells
(936 1%, P\0.0001), while iCasp9– cells retained an apoptosis
index similar to that of non-transduced controls (206 7%,
P5 0.99 and P5 0.69 vs. non-transduced controls with or with-
out CID respectively), demonstrating that iCasp9+ MSCs can be
selectively killed. Addition of CID to cultures of differentiated
MSCs resulted in widespread apopotosis as assessed by TUNEL
assay. Furthermore, using an in vivo imaging system, we saw that
iCasp9+ MSCs injected subcutaneously in SCID mice were selec-
tively eliminated after administration of CID, without toxic ef-
fects.
In summary, MSCs are easily transduced with our iCasp9 sys-
tem, the transduced cells can be selected with clinical grade pro-
cedures and maintain their basic physiology, and their
differentiated progeny can be selectively eliminated by exposure
to a CID, analogues of which have been safely tested in a phase
I study. This directed MSC killing provides a necessary safety
mechanism for therapies using progenitor cells. This approach
will become of increasing value as clinical applications for MSCs
develop further.
